Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Trade this ETF at your broker
| Investment approach | Long-only |
| Index | Nasdaq Biotechnology |
| Investment focus | Aandelen, Verenigde Staten, Gezondheidszorg |
| Fund size | EUR 69 m |
| Total expense ratio | 0,35% p.a. |
| Replication | Physical (Optimized sampling) |
| Legal structure | ETF |
| Sustainability | No |
| Fund currency | USD |
| Currency hedged | No |
| Inception/ Listing Date | 5 maart 2018 |
| Distribution policy | Distributing |
| Distribution frequency | Semi annually |
| Fund domicile | Ierland |
| Fund Provider | iShares |
| Germany | 30% belastingvermindering |
| Switzerland | ESTV Reporting |
| Austria | Belastingrapportagefonds |
| UK | UK-rapportage |
| Italy | 26,0% |
| Fund Structure | Open-ended Investment Company (OEIC) |
| UCITS compliance | Yes |
| Administrator | State Street Fund Services (Ireland) Limited |
| Investment Advisor | |
| Custodian Bank | State Street Custodial Services (Ireland) Limited |
| Revision Company | Deloitte |
| Fiscal Year End | 31 mei |
| Swiss representative | BlackRock Asset Management Schweiz AG |
| Swiss paying agent | State Street Bank International GmbH, Munich, Zurich Branch |
| Indextype | Total return index |
| Swap counterparty | - |
| Collateral manager | Bank of New York Mellon|Euroclear|JP Morgan|State Street Bank |
| Securities lending | Yes |
| Securities lending counterparty | Barclays Bank Plc|Barclays Capital Securities Ltd.|BNP Paribas Arbitrage SNC|BNP Paribas SA|Citigroup Global Markets Ltd|Citigroup Inc|Credit Suisse Securities (Europe) Ltd.|Deutsche Bank AG|Goldman Sachs International|HSBC Bank Plc|J.P. Morgan Securities Plc|JP Morgan Chase & Co|Macquarie Bank Limited|Merrill Lynch International|Morgan Stanley & Co. International Plc|Nomura International Plc|Skandinaviska Enskilda Banken AB|Societe Generale SA|The Bank of Nova Scotia|UBS AG |
| Gilead Sciences, Inc. | 8,15% |
| Amgen, Inc. | 7,83% |
| Vertex Pharmaceuticals | 7,67% |
| Moderna, Inc. | 5,03% |
| Regeneron Pharmaceuticals, Inc. | 5,02% |
| Revolution Medicines | 2,88% |
| Illumina, Inc. | 2,70% |
| Biogen | 2,18% |
| Alnylam Pharmaceuticals | 2,16% |
| Roivant Sciences Ltd. | 1,73% |
| Broker | Rating | Execution fee | Account fee | |
|---|---|---|---|---|
| | 0,00 € | 0,00 € | Voir l'offre** | |
| | 0,00 € | 0,00 € | Voir l'offre* | |
| | 0,00 € | 0,00 € | Voir l'offre* |
| YTD | +31.32% |
| 1 month | +5.01% |
| 3 months | +5.98% |
| 6 months | +29.66% |
| 1 year | +31.87% |
| 3 years | +84.03% |
| 5 years | +52.99% |
| Since inception (MAX) | +129.08% |
| 2025 | +17.31% |
| 2024 | +5.34% |
| 2023 | +0.76% |
| 2022 | -5.13% |
| Huidig dividendrendement | 0,20% |
| Dividends (last 12 months) | EUR 0,02 |
| Period | Dividend in EUR | Dividend yield in % |
|---|---|---|
| 1 jaar | EUR 0,02 | 0,27% |
| 2025 | EUR 0,03 | 0,44% |
| 2024 | EUR 0,03 | 0,47% |
| 2023 | EUR 0,02 | 0,40% |
| 2022 | EUR 0,03 | 0,42% |
| Risk indicator |
Lower risk Higher risk |
| Volatility 1 year | 22.69% |
| Volatility 3 years | 21.65% |
| Volatility 5 years | 22.94% |
| Return per risk 1 year | 1.40 |
| Return per risk 3 years | 1.04 |
| Return per risk 5 years | 0.39 |
| Maximum drawdown 1 year | -7.03% |
| Maximum drawdown 3 years | -25.58% |
| Maximum drawdown 5 years | -25.58% |
| Maximum drawdown since inception | -31.04% |
| Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| gettex | EUR | OM3E | - - | - - | - |
| London Stock Exchange | USD | BTEE | BTEE LN INAVBTDU | BTTE.L |